Coherus and Zumutor Collaborate on ZM008 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Coherus Oncology and Zumutor Biologics announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a NK checkpoint anti-LLT1 monoclonal antibody in combination with Loqtorzi, a PD-1 inhibitor. The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. Under the terms of the greement, Coherus will provide Loqtorzi to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial. Zumutor and Coherus each retain all commercial rights to their respective compounds, as monotherapies or combination therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.560
Low
4.00
Averages
5.50
High
7.00
Current: 1.560
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus and Zumutor Announce Clinical Collaboration for ZM008
- Clinical Collaboration Agreement: Coherus Oncology and Zumutor Biologics have signed a clinical collaboration and supply agreement to study the novel anti-tumor monoclonal antibody ZM008 in conjunction with the PD-1 inhibitor LOQTORZI in a Phase 1 trial, aimed at evaluating its efficacy across various solid tumors.
- Patient Recruitment Plan: The study will enroll up to 45 patients, covering colorectal, head and neck, and non-small cell lung cancers, indicating potential therapeutic value for multiple hard-to-treat cancers and possibly providing new treatment options for patients.
- Safety and Tolerability Assessment: ZM008 has demonstrated a favorable safety profile in monotherapy studies, with no dose-limiting toxicities or anti-drug antibodies reported, and early clinical activity has been observed in metastatic patients previously treated with immune checkpoint inhibitors, suggesting its potential in
See More
Coherus and Zumutor Collaborate on Phase 1 Clinical Trial
- Clinical Collaboration Agreement: Coherus Oncology and Zumutor Biologics have signed a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008 in combination with LOQTORZI, aiming to evaluate its efficacy across various solid tumors, marking a strategic expansion in the oncology immunotherapy field.
- Trial Design and Patient Recruitment: The trial plans to enroll up to 45 patients to assess the safety and tolerability of ZM008, particularly in hard-to-treat cancer patients, highlighting a strong demand for novel immunotherapy options and potentially laying the groundwork for future personalized treatments.
- Innovative Drug Potential: ZM008 has demonstrated favorable clinical outcomes in monotherapy, especially in metastatic patients previously unresponsive to immune checkpoint inhibitors, further validating its application potential in
See More
Coherus Oncology Q1 2026 Earnings Call Insights
- LOQTORZI Revenue Projections: CEO Dennis Lanfear stated that LOQTORZI is projected to generate about $175 million annually in nasopharyngeal cancer, with expectations of reaching $15 million per quarter in 2026 and $30 to $35 million per quarter in 2027, indicating strong market potential.
- R&D Spending and Financing: CFO Bryan McMichael reported Q1 2026 R&D expenses of $21.5 million and total net proceeds of $54 million, providing financial backing for future clinical trials and market expansion efforts.
- Sales Dynamics and Market Performance: Despite Q1 LOQTORZI net sales of $11.8 million, a decline from the previous quarter, CCO Sameer Goregaoker highlighted record new patient starts, demonstrating sustained market demand.
- Future Outlook and Data Releases: Management anticipates quarterly demand growth of 10% to 15% throughout 2026 and plans to provide full-year 2026 revenue guidance during the August earnings call, further bolstering investor confidence.
See More
CHRS Q1 2026 Earnings Transcript
See More
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus and Zumutor Announce Clinical Collaboration for ZM008
- Clinical Collaboration Agreement: Coherus Oncology and Zumutor Biologics have signed a clinical collaboration and supply agreement to study the novel anti-tumor monoclonal antibody ZM008 in conjunction with the PD-1 inhibitor LOQTORZI in a Phase 1 trial, aimed at evaluating its efficacy across various solid tumors.
- Patient Recruitment Plan: The study will enroll up to 45 patients, covering colorectal, head and neck, and non-small cell lung cancers, indicating potential therapeutic value for multiple hard-to-treat cancers and possibly providing new treatment options for patients.
- Safety and Tolerability Assessment: ZM008 has demonstrated a favorable safety profile in monotherapy studies, with no dose-limiting toxicities or anti-drug antibodies reported, and early clinical activity has been observed in metastatic patients previously treated with immune checkpoint inhibitors, suggesting its potential in
See More
Coherus and Zumutor Collaborate on Phase 1 Clinical Trial
- Clinical Collaboration Agreement: Coherus Oncology and Zumutor Biologics have signed a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008 in combination with LOQTORZI, aiming to evaluate its efficacy across various solid tumors, marking a strategic expansion in the oncology immunotherapy field.
- Trial Design and Patient Recruitment: The trial plans to enroll up to 45 patients to assess the safety and tolerability of ZM008, particularly in hard-to-treat cancer patients, highlighting a strong demand for novel immunotherapy options and potentially laying the groundwork for future personalized treatments.
- Innovative Drug Potential: ZM008 has demonstrated favorable clinical outcomes in monotherapy, especially in metastatic patients previously unresponsive to immune checkpoint inhibitors, further validating its application potential in
See More
Coherus Oncology Q1 2026 Earnings Call Insights
- LOQTORZI Revenue Projections: CEO Dennis Lanfear stated that LOQTORZI is projected to generate about $175 million annually in nasopharyngeal cancer, with expectations of reaching $15 million per quarter in 2026 and $30 to $35 million per quarter in 2027, indicating strong market potential.
- R&D Spending and Financing: CFO Bryan McMichael reported Q1 2026 R&D expenses of $21.5 million and total net proceeds of $54 million, providing financial backing for future clinical trials and market expansion efforts.
- Sales Dynamics and Market Performance: Despite Q1 LOQTORZI net sales of $11.8 million, a decline from the previous quarter, CCO Sameer Goregaoker highlighted record new patient starts, demonstrating sustained market demand.
- Future Outlook and Data Releases: Management anticipates quarterly demand growth of 10% to 15% throughout 2026 and plans to provide full-year 2026 revenue guidance during the August earnings call, further bolstering investor confidence.
See More
CHRS Q1 2026 Earnings Transcript
See More
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
